In drug development, that means showing how models are trained, which data are used, and how predictions of safety and ...

Zelasudil, a potential best-in-class, selective ROCK2 inhibitor shows evidence of anti-fibrotic activity at 12 and 24 weeks in patients with IPFZelasudil reduces FVC decline numerically at 12 weeks ...

Gender gap in health reveals that medical research has historically overlooked women, leading to misapplied treatments and ...

Experts at ASHG 2025 will tackle clinical and genetic research challenges on sex, gender and sexuality, exploring ethics, ...

AI/ML technologies are revolutionizing pharmaceutical formulation by optimizing excipient selection and predicting stability, reducing time and resources needed for development. Poor solubility of ...

A large trial reveals that boosting testosterone does not influence men's economic preferences, challenging previous studies ...

Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations –MELBOURNE, Australia and SAN ...

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe ...

ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses ...

Some of the key facts of the Clostridium Difficile Infections Market Report: ...

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...